MD Anderson to Perform Clinical Validation Study for Rosetta Genomics' CUP Test | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the University of Texas MD Anderson Cancer Center will perform a clinical validation study for its microRNA-based test designed to locate the primary site of cancers of unknown primary origin.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.